Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for ENHERTU October 4, 2022October 4, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: Roche's Kadcyla is the first targeted therapy…Eight-year data from APHINITY study show Roche’s…Roche’s inavolisib combination reduces the risk of…Roche announces positive Phase III results for…Roche launches two new antibodies to identify key…Roche launches PRAME (EPR20330) Antibody to identify…
